M.D., FESC, FACC
Physician, Cardiologist | Translational Researcher, Trialist | Innovator
Pioneer of Cardiovascular Nanomedicine
General Cardiology, Interventional Cardiology | Imaging (QCA, IVUS, OCT, TTE, CMR, MSCT) |
RTD, Biomedical Engineering, Nanomedicine, Coronary Devices | Gender-Based Medicine |
Public Health Management, Advocacy in Cardiology and Innovations | Sleep Medicine |
Longevity, Frailty | Consciousness, Singularitarianism, Transhumanism | Anti-Russian Sentiment
Dr Kharlamov has 23 years of the clinical experience in general cardiology (since 1996; a Consultant Physician since 2007, a Board-Certified Cardiologist since 2010), 18 years of the translational research in nanomedicine and biomedical engineering (since 2001), and about 12 years of the bench-to-bedside studies in interventional cardiology (a leader of the research group since 2007) including imaging, vascular biology and pathology, RTD of medical devices (bioresorbable scaffolds and stents). He has moved to Russia in babyhood having American, Dutch and British roots, and has received his M.D. (Doctor of Medicine) cum laude in 2005 from Ural Medical University (Yekaterinburg, Russia). After finishing his internship in internal medicine in 2007 in Ural Institute of Cardiology (mentor - Prof. Jan Gabinsky, Yekaterinburg, Russia) he started as a physician and translational researcher (a group leader as an Assistant Professor) in the field of interventional cardiology and nanobiotechnologies. The main research direction now is an RTD of the multifunctional nanoparticles for theranostics of atherosclerosis. He is an inventor of the revolutionary application which has the potential to replace conventional stenting and CABG. He has passed his C.Sc.-doctoral/ graduate degree course in cardiology (A.B.D.) at the Ural Medical University in 2008-2011. Since 2007-2009 he has been working as a research fellow in some institutes in the Netherlands (UMC St Radboud, Nijmegen; UMCG, Groningen; Erasmus MC, Rotterdam including mentorship of the renowned Prof. Patrick Serruys). He is an author of more than 60 articles and grant proposals for the European Commission and has received for his research work some national and international awards. Since Dec 2018 he is a FESC, and Jan 2019 - a FACC, May 2019 - a FEACVI (elect; in effect since Jan 2020).
h-index = 6 (Web of Science, Publons), 8 (Scopus, Google Scholar, ResearchGate). The publication profile is available in ResearchGate, PubMed (akharlamov@orcid), ORCiD (0000-0003-4631-1261), ResearcherID (I-3692-2015), Russian Science Index (7738-9429), and Scopus (56721449700). The editorial/ reviewer profile (Local editorial board member in EuroIntervention in 2011-2013, member of the International Editorial Board in European Heart Journal in 2013-2015, consulting editor in both Cardiovascular Diagnosis and Therapy in 2013-2017, and International Journal of Nanomedicine in 2013-2019), member of the Editorial Board in World Journal of Cardiology (since 2018) is available in Publons (publons.com/a/1136995/).
European Society of Cardiology - ESC (since 2006; FESC since 2018), American College of Cardiology - ACC (since 2009; FACC since 2019), American Heart Association - AHA (since 2009), International Society for Stem Cell Research - ISSCR (since 2009), International Society of Nephrology - ISN (since 2009), European Society for Nanomedicine - ESNM (since 2011), The Society for Cardiovascular Angiography and Interventions - SCAI (since 2017), World Sleep Society - WSS (since 2018), The British Society for Nanomedicine - BSN (since 2018), Royal College of Physicians of London - RCP (since 2019), International Society for Cardiovascular Translational Research - ISCTR (since 2019), American Association for the Advancement of Science - AAAS (since 2019).
Our mission is to inspire and drive the breaking ground research in cardiovascular clinical practice taking the lead in translational and clinical studies, managing cardiovascular imaging service, contributing to the development of the novel imaging tools, medical devices, promising biomedical engineering and nanotechnology solutions, national and international professional standards of health care in general and interventional cardiology, cardiovascular imaging, disseminating the knowledge to the scientific professional community and general public, supporting the highest standards of quality and safety in both imaging and therapy in order to pave the way toward the dramatic reduction of cardiovascular burden across the globe rescuing millions of lives.
De Haar Research Task Force (DHRF, DHRF Pro)
Registered with CoC/ KvK: 75124408
VAT/ BTW: NL6778.86.767.B01
The structure of DHRF includes three labs:
1) J.A. Cramer K. Translational Research Lab for Cardiovascular Nanomedicine (Cramer Lab) with a focus on translational research in biomedical engineering, nanomedicine and regression of atherosclerosis
2) L. da Vinci Cardiovascular Imaging Lab (Da Vinci Lab) is a sort of the CoreLab with the expert analysis of both invasive and non-invasive (interventional/ intravascular) techniques in cardiology
3) M. Van Buren Trialist Lab (Van Buren Lab) is essentially an assistant and management research service to the clinical trials in general and interventional cardiology
De Haar Research Task Force
Dr Alexander N. Kharlamov MD FESC FACC is a Founder and Executive manager of the Task Force/ DHRF (a.k.a. De Haar Research Foundation) which is essentially a small self-employed enterprise. The idea of DHRF was born in Rotterdam on February 15th, 2013. Task Force develops and supports innovations in interventional cardiology, medical device development, intracoronary/ intravascular and non-invasive imaging (QCA, IVUS, OCT, CTA, CMR, TTE, photoacoustics), biomedical engineering, neurophysiology (mostly, consciousness), PET-imaging, and nanomedicine (multifunctional nanoparticles for theranostics of atherosclerosis). The DHRF provides start-ups and small enterprises in the United States and countries of the Commonwealth of Nations with the relevant research service and assistance representing, promoting and supporting their biomedical business in Europe as well as the relevant translational and clinical studies including CE mark procedures. The DHRF currently is an SME-business located in Rotterdam and Amsterdam (the Netherlands) with ambitions of the further development and expansion inside the Lowlands, Europe and in the United States. The minimum price contract (valid until 31 December, 2019) is 4,946.08 EUR per month (a consultancy from 123.7 EUR per hour).
Thus, De Haar Research Task Force provides the service as follows:
consultancy in cardiovascular nanomedicine (translational studies)
medical device consultancy in interventional cardiovascular biomedicine (vascular biology, biomedical engineering, coronary devices, interventional cardiology, translational studies)
clinical trial management in Russia (no E.U. or U.S. requirements are needed) and Europe - special support for the U.S., E.U., Asian preclinical or clinical trial sponsors/ enterprises (including start-ups with the proof-of-concept studies) with the European scientific back-up
scientific assistance of applications for CE mark and FDA in interventional cardiovascular and nanomedical topics
medical concierge service in Russia for foreigners (any medical conditions and diseases), medical tourism in the European Union and the Netherlands
independent expert imaging CoreLab-like analysis of QCA, OCT, IVUS (with the professional validated software)
scientific assistance of the independent (external) imaging software validation
Grant writing for European Commission
scientific article writing
medical device and software proctoring service
Please, Support our Task Force and Research Initiative!
All together we can revolutionize cardiology and save millions of lives!
Mapping Twitter followers
Social and Scientific Networking
Analytics of Followers
GET IN ToUCH!
VISITORS STRICTLY BY APPOINTMENT ONLY 24/7
Dr Alexander Kharlamov
T.a.v. Unit 303-G9950